Vosoritide Patent Expiration
Vosoritide is used for promoting linear growth in pediatric patients with achondroplasia. It was first introduced by Biomarin Pharmaceutical Inc
Vosoritide Patents
Given below is the list of patents protecting Vosoritide, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Voxzogo | US12233106 | C-type natriuretic peptide variants to treat skeletal dysplasia in children | Jul 11, 2042 | Biomarin Pharm |
| Voxzogo | US10646550 | Use of C-type natriuretic peptide variants to treat skeletal dysplasia | Aug 01, 2036 | Biomarin Pharm |
| Voxzogo | US11590204 | Use of C-type natriuretic peptide variants to treat skeletal dysplasia | Aug 01, 2036 | Biomarin Pharm |
| Voxzogo | US11911446 | Use of C-type natriuretic peptide variants to treat skeletal dysplasia | Aug 01, 2036 | Biomarin Pharm |
| Voxzogo | US12514906 | Use Of C-Type Natriuretic Peptide Variants To Treat Skeletal Dysplasia | Aug 01, 2036 | Biomarin Pharm |
| Voxzogo | US9907834 | Use of C-type natriuretic peptide variants to treat skeletal dysplasia | Aug 01, 2036 | Biomarin Pharm |
| Voxzogo | US8198242 | Variants of C-type natriuretic peptide | Jun 11, 2035 | Biomarin Pharm |
| Voxzogo | USRE48267 | Variants of C-type natriuretic peptide | May 20, 2030 | Biomarin Pharm |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Vosoritide's patents.
Latest Legal Activities on Vosoritide's Patents
Given below is the list recent legal activities going on the following patents of Vosoritide.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Notice of Final Determination -Eligible | 30 Dec, 2025 | US8198242 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 21 Aug, 2025 | US9907834 |
| FDA Final Eligibility Letter | 10 Jun, 2025 | US8198242 |
| transaction for FDA Determination of Regulatory Review Period | 04 Mar, 2024 | US8198242 |
| transaction for FDA Determination of Regulatory Review Period | 28 Feb, 2024 | US8198242 |
| Second letter to regulating agency to determine regulatory review period | 05 Jan, 2024 | US8198242 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 21 Nov, 2023 | US8198242 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 19 Oct, 2023 | US10646550 |
| Letter from FDA or Dept of Agriculture re PTE application | 28 Sep, 2023 | US8198242 |
| Initial letter Re: PTE Application to regulating agency | 03 Aug, 2022 | US8198242 |
Vosoritide's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Vosoritide:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment | BioMarin Pharmaceutical | NA |
ACTIVE NOT RECRUITING
(Sep 1, 2026)
| PHASE2 |
| Long-Term Extension Study of Vosoritide to Treat Children With Hypochondroplasia | BioMarin Pharmaceutical | NA |
ENROLLING BY INVITATION
(Sep 1, 2026)
| PHASE3 |
| Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia | BioMarin Pharmaceutical | NA |
RECRUITING
(Sep 1, 2026)
| PHASE2, PHASE3 |
| A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature | BioMarin Pharmaceutical | NA |
RECRUITING
(May 1, 2026)
| PHASE2 |
| A Clinical Trial to Evaluate Safety of Vosoritide in At-risk Infants With Achondroplasia | BioMarin Pharmaceutical | NA |
ACTIVE NOT RECRUITING
(Mar 1, 2026)
| PHASE2 |